Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01904123CT.gov STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | — | Completed | — | — | — |
NCT02974621CT.gov Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | — | Active Not Recruiting | — | — | — |
NCT03216499CT.gov HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma | — | Completed | — | — | — |
NCT03020017CT.gov NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery | — | Completed | — | — | — |
NCT03020602CT.gov BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab | — | Completed | — | — | — |
NCT02101905CT.gov Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | — | Completed | — | — | — |
NCT02658981CT.gov Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | — | Completed | — | — | — |
NCT02192359CT.gov Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | — | Active Not Recruiting | — | — | — |
NCT02323880CT.gov Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | — | Completed | — | — | — |
NCT02337686CT.gov Pembrolizumab in Treating Patients With Recurrent Glioblastoma | — | Active Not Recruiting | — | — | — |
Show 13 more trialsShow fewer
NCT02255461CT.gov Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | — | Terminated | — | — | — |
NCT02133183CT.gov Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | — | Terminated | — | — | — |
NCT01922076CT.gov Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | — | Completed | — | — | — |
NCT01609790CT.gov Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | — | Completed | — | — | — |
NCT01522820CT.gov Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | — | Completed | — | — | — |
NCT01514201CT.gov Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | — | Completed | — | — | — |
NCT01310855CT.gov Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma | — | Terminated | — | — | — |
NCT01172964CT.gov A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas | — | Completed | — | — | — |
NCT00777153CT.gov Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma | — | Completed | — | — | — |
NCT00679354CT.gov Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy | — | Completed | — | — | — |
NCT00503204CT.gov Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour | — | Completed | — | — | — |
NCT00095940CT.gov Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | — | Completed | — | — | — |
NCT00042991CT.gov Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cediranib (this asset) | M.D. Anderson Cancer Center | P3 | BB · 66 |
| Depatuxizumab Mafodotin | AbbVie | P3 | BB |
| Cintredekin Besudotox | INSYS Therapeutics Inc | P3 | BB |
| Camustine | Leland Metheny | P3 | BB |
| (+)-Vincristine | University of Cincinnati | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Capecitabine | Northwell Health | P2 | BB |
| Lomustine | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
| Carboplatin | Sichuan Honghe Biotechnology Co., Ltd. | P3 | BB |
+42 more in the Glioblastoma cohort
Other indications for Cediranib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | BBB · 76 |
| Metastatic Melanoma | — | P2 | BBB · 73 |
| Adult Glioblastoma | — | P2 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cediranib in Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cediranib-glioblastoma-24322
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →